Objective: To evaluate four Enzyme Linked Immunosorbent Assay ( ELISA) HIV kits for possible use as a combination at the National Health Laboratory Services (NHLS) in Zimbabwe.
Introduction
The Human Immunodeficiency Virus (HIV) antibody testing remains a critical component as well as a pre requisite for evolving effective strategies in the control of the HIV epidemic.1 HIV testing is useful for diagnostic purposes; screening of blood donors and blood units; monitoring the epidemic through surveillance of sentinel population and healthy volunteers wanting to know their HIV status.2 The poor prognosis associated with a positive diagnosis means that diagnostic tests must not only be sensitive but also highly specific. Unfortunately, HIV antibody testing algorithms involving Western Blot (WB) or line immunoassays for confirmation of infection, are not always readily feasible in developing nations due to combinations of political unrests, worsening economic circumstances, cost, absence of ancillary equipment, long turn around time and the increasing number of HIV infections to be confirmed2 as well as absence of adequate quality control measures.
Several antibody-testing strategies involving different Enzyme Linked Immunosorbent Assay (ELISA) kits, have been developed for a number of settings and populations. Since the first tests became available in 1985, the specificity and sensitivity of these kits have increased and their use has become widespread in both developed and developing countries. A single HIV antibody test may not be enough to give reliable results. 3 In an attempt to standardize HIV testing algorithms, the World Health Organization (WHO) devised HIV testing procedures for developing countries to adopt, which depending on purpose of testing and HIV prevalence, maximize accuracy and minimizes costs.45 Ideally, the strategy is to replace expensive, time consuming and subjective WB with a combination of ELISA kits that utilize different antigens and have different test principles.4 '7 Although combinations of assays have been evaluated in other countries before, it was found necessary to evaluate the strategy in a local situation with serum samples obtained from the local population. This is of major importance in Africa where serological assays, utilized in the developed countries have shown lower sensitivity and specificity. 6 Thus assay evaluations will also seek to include newly developed kits that have not been included in previous evaluation exercises.
The main objective of this study was to evaluate four commercially available HIV ELISA kits namely: Murex HIV 1.2.0 (Abbott Laboratories, USA); ICE* HIV 1.0.2 (Murex Biotech LTD, UK); Labsystems HIV EIA and Innotest™ HIV Ab 1.0.2 (Innogenetics, Belgium) for possible use in Zimbabwe.
The specific objectives were to determine: (i) The sensitivity and specificity of the kits individually and in parallel combination. (ii) The best combination of assays with, different test principles, widest range of viral antigenic preparations and ability to detect antibodies to HIV-1 (groups M and O) as well as HIV-2.
(iii) The best combination producing minimal discordant results, but with maximum sensitivity and specificity. (iv) The cost effectiveness of the combinations and to assess whether quality of results should be sacrificed for cost or vice-versa. (v) To compare the cost effectiveness of using the expensive and unreliable WB,3 611 with a third ELISA kit as confirmatory test for discordant results as deemed by two ELISA kits of choice.
Materials and Methods

Samples.
A total of 346 samples with confirmed HIV-1 status as determined by the gold standard (two ELISA kits and WB) was used for the evaluation exercise. The use of two independent ELISA kits and Western Blot as the gold standard is in accordance with Centers for Disease Control12 and World Health Organization recommendations. 13 One hundred and one samples were obtained from low risk voluntary blood donors presenting at BTS and 245 samples were obtained from consecutive patients who were from various high risk groups that included out patients referred by doctors for HIV testing, patients admitted at Parirenyatwa Hospital (not necessarily AIDS patients) and also patients referred for haematological investigations at the haematology laboratory. A high proportion of high risk samples was used in the evaluation panel because of the information gain of a test. This test is defined as the difference between the pre-and post test probability of a disease and is greatest when the pretest probability is between 40% and 60%; representing a range in which an assay can most effectively confirm or rule out infection.14 Determination of HIV status of samples by ELISA and Western Blot.
The HIV status of 350 samples was determined using the gold standard com prising Genelavia Mixt (Sanofi Diagnostics Pasteur, France) and Vironostika HIV uniform II plus 0 (Organon Teknika, Netherlands) ELISA kits and WB (Abbot Diagnostics, South Africa) in accordance with instructions provided by the manufacturer. The Genelavia Mixt detects antibodies to, HIV-1 gp41 and gpl60 as well as HIV-2 gp36 antigens. The Vironostika HIV uniform II plus O detects antibodies to p24, gpl60 and ANT 70 peptide and HIV-2 gp36 antigens. A specimen that had concordant positive results by the two ELISA tests was classified as HIV positive. A specimen that had concordant negative results by the two ELISA tests was classified as HIV negative. Discordant and indeterminate results obtained from the two ELISA tests were resolved by WB. Three hundred and forty six samples of known HIV status were selected and used for the evaluation of the four kits, namely: (i) Murex HIV-1. All assays were carried out according to the manufacturers's instructions.
Statistics.
Specificity was defined as the percentage of gold standard HIV-negative confirmed samples that were negative by the kit under evaluation. The specificity of the combined assays was defined as the percentage of HIV negative confirmed specimens that were concordantly negative when tested using the two kits in parallel and was calculated using the same formula as that used for calculating the specificity of a single kit:
Sensitivity was defined as the percentage of gold standard confirmed HIV antibody positive samples found reactive by assay under evaluation. The sensitivity of the combined kits was defined as the percentage of gold standard confirmed HIV antibody positive specimens found reactive concordantly by the two kits when used in parallel and was calculated using the same formula as that used for calculation of the sensitivity for a single kit.
Positive predictive value (PPV) was defined as the probability that a serum contains antibodies to HIV when the test was positive. The PPV for the combined kits was defined as the probability that a specimen contains anti-HIV antibodies when the test was concordantly positive using the two kits.in parallel.
Negative Predictive Value (NPV) was defined as the probability that a serum does not have antibodies to HIV when the test was negative. The NPV for the combined kits was defined as the probability that a specimen does not contain antibodies to HIV when the test was concordantly negative using the two kits in parallel.
When calculating PPV and NPV, a prevalence rate of 35% HIV infection was taken into consideration for the high risk group, based on estimates from an ongoing clinical trial of postpartum vitamin A supplementation aimed at reducing postnatal transmission of HIV (Zijenah et al., unpublished data) whilst a prevalence rate of 2% was used for the low risk group i.e BTS group (BTS surveillance data).
Test efficiency refers to the overall ability of a test to correctly identify all positives and negatives (the absence of false positives and false negatives). It is a combination of the sensitivity and the specificity of an assay and gives an idea of the total effectiveness of the assay.
Results
Characteristics of the four ELISA kits.
The general characteristics of the assays under evaluation compared with the kits currently in use at the NHLS are shown in Table I . All the six kits detect IgM and IgG antibodies to HIV-1 group M and HIV-2 antigens. Only the Labsystems and Genelavia kits could not detect antibodies to the HIV 1 group O. The Murex kit was the only kit that could detect IgA anti-HIV antibodies. The average sample volume was 50pl for all the kits except Genelavia which required 20pl. Murex, Ice and Vironostika kits are sandwich assays whereas Labsystems, Innotest and Genelavia are indirect assays. Performance of the four ELISA kits using low risk specimens from BTS.
The results of the performance of the four ELISA kits under evaluation when tested on low risk samples (101) from BTS are shown in Table II . Based on the gold standard, 99 samples (99/101, 98.2%) were classified as HIV negative whilst two (2/101,19.8%) were HIV positive. Innotest had the highest number of false positive results, seven, whilst Labsytems had the least, one. The number of false positives obtained using the Murex and Ice kits was three and four respectively. None of the kits gave any false negative results. Performance of the four ELISA kits using high-risk specimens from the NHLS.
The results of the performance of the four ELISA kits under evaluation when used on high risk samples (246) from Parirenyatwa Hospital are shown in Table III respectively whilst Innotest had the lowest number of indeterminate and false positive results of two and one respectively. Performance of the four ELISA kits using combined low and high risk samples.
The results obtained when the four ELISA kits under evaluation were used on the two sets of samples when tested as one batch are shown in Table IV . Of the 346 samples used in the evaluation, 123 (35.5%) were found to be HIV positive whilst 223 (64.5%) were found to be HIV negative by the gold standard. The four kits had a very high number of false positive results of 21,15,14 and eight for Murex, Ice, Labsystems and Innotest respectively. Murex and Labsystems had the same number of indeterminate samples of seven each. Murex had the highest number of true positives (n=122) whilst Labsystems had the least (n= 116). Innotest had the highest number of true negatives (n=213) whilst the Murex had the lowest (n=195). Comparison of sensitivity, specificity, test efficiency, PPV and NPV of the four kits.
All the results from Tables II, III and IV were used to calculate the above five parameters for the four kits under evaluation for the low risk group (BTS), high risk group (PHL) and all combined (All).
For all samples combined (All), all the assays had good sensitivity except Labsystems with 94.3% Table V. The specificity was lower than 95% for all assays except Innotest with 96.4%. The PPV for all the assays was lower than 95%, however the negative predictive value was quite high, greater than 95% for all assays with Labsystems yielding the lowest value of 96.7%. The Innotest kit was the most efficient kit with 96.2% whilst the other three had Test efficiencies lower than 95%. For the low risk samples (BTS), all the kits had an excellent sensitivity of 100% (Table VI) . The specificity of the three kits (Murex, Labsystems and Ice) was greater than 95%. Innotest had a relatively lower specificity of 92.9% compared to the other kits. The PPV on BTS samples was very low with three assays yielding less than 50%. Labsystems had the highest PPV of 66.6%. The NPV ofall the four kits was 100%.TheTest efficiency ofMurex, Ice and Labsystem kits was greater than 95% whilst that of the Innotest kit was only 93.1%. For the high risk samples (NHLS), the sensitivity obtained with Murex, Ice and Innotest kits was greater than 95% (V II). The sensitivity of the Labsystems kit was slightly lower (94.2%). The specificity on the NHLS samples was low for three of the kits (less than 95%). Innotest had a relatively high specificity of 99.1%. The NPV was greater than 95% for three kits except for Labsystems with 88.4%. The Innotest kit was the most efficient kit with 97.5% whilst the other three had efficiencies lower than 95%. Performance of Kits when Evaluated as a Combination. Table IX shows results of the performance of the four anti-HIV antibody test kits when used as a combination. The calculations of specificity and sensitivity for the combinations of assays were based on concordant results for all assays included in each combination when tests were performed in parallel. The sensitivity and specificity was greater than 95% for all parallel combinations. Also included in the table is the % discordance and % concordance. The PPV and NPV for the six possible combinations were greater than 95%.
Comparison of Western Blot Confirmation with ELISA Confirmation.
The cost of using WB or ELISA as a confirmatory test for discordant results was compared and the results are shown in Table VI . The average price of ELISA kits of $ 105 was used as a comparison to using Western Blot for confirmation of discordant results. 
Discussion
The high number of false positives obtained using the three kits, Murex, Ice and Labsystems was responsible for lowering the specificity and PPV of the kits. Innotest with the lowest number of false positives had the highest specificity with the best ability to pick out more negatives compared to Murex, Ice and Labsystems. The 96.4% specificity is comparable to that of Genelavia and Vironostika; 97.5% and 98.7% respectively.On the other hand Murex, with lowest number of false negatives had the highest sensitivity, and was therefore able to identify the majority of the HIV positive samples. The 99.0% sensitivity obtained using the Murex kit compares very well with that of Genelavia and Vironostika (99.6% and 99.4% respectively).When diagnosis is uncertain, an HIV test may be indicated since the result could influence decisions on diagnostic procedures and therapy. For example, in a patient with a focal neurological deficit, a positive HIV test would justify the start of treatment for toxoplasmosis whilst a negative result would preclude such treatment because of the toxicity of the drugs.; Other important decisions that are taken in hospitals concerning treatment of patients such as operations and blood transfusion also depend on the knowledge of the HIV status of the patients; therefore it is important to have kits that produce accurate results. Of interest to note are the striking differences in the numbers of false negatives and false positives, when high risk samples (NHLS) and low risk donor samples (BTS) were tested separately. All the kits under evaluation showed fewer false positives on BTS samples in comparison with NHLS samples. Similarly, a number of false negatives were obtained with NHLS samples whilst none were obtained when BTS samples were tested.
The PPV of all the four kits under study was lower on the BTS samples compared to the NHLS samples. On the other hand, the NPV was 100% when all the kits were evaluated using BTS samples in sharp contrast to the relatively low NPV obtained when the kits were evaluated using PHL samples.
The NPV was highest with BTS samples due to the low prevalence of HIV infection amongst low risk blood donors resulting in low number of false negatives and high number of true negatives. On the other hand the PPV was low with BTS samples compared to the NHLS samples due to the low prevalence of HIV infection amongst low risk blood donors leading to a higher number of false positives and low number of true positives as compared to low false positives and high number of true positives amongst the high risk group. The differential sensitivity, specificity, PPV and NPV results from the low risk and high risk groups when assessed separately, reinforce the importance of including samples from both groups not only when evaluating new kits but also when determining the prevalence of an infection or disease in a population under study.
The discussion below is based on the evaluation of the four kits using the 346 specimens as an entity rather than subdivided into low and high risk specimens.
Because the kits to be selected were to be used in parallel, it was found necessary to combine the kits in order to determine the concordance and discordance of the chosen kits. Combining the kits improved the overall sensitivity and specificity of all the combinations investigated. All the three combinations involving Murex i.e. Murex/Ice, Murex/ Labsystems and Murex/Innotest had sensitivity of 100% due to the absence of concordantly false negative results in these combinations.
In all combinations, there were fewer false positive and false negative results when compared to individual kits because when the kits are combined the probability that two kits concordantly produce a false result is very low. The false results obtained in the study were probably due to random and independent errors as opposed to systematic errors. Random errors occur due to technical problems during sample pipetting, inefficient washing and use of haemolysed samples. Systematic errors may have been caused by cross reactions with other non-specific IgG, IgM or IgA antibodies in patients' serum associated with microbial infections such as malaria or autoimmune conditions and these are almost always not independent.6 Such conditions are usually accom panied by hypergammaglobulinaemia. The fact that errors were both random and independent is reflected also in the large number of discordant results.
Interestingly, using the kits as acombination undisputedly improved the diagnostic accuracy of kits with a significant decrease in the overall number of false positives and false negatives whilst the number of discordant results increased sharply when compared to those of individual kits. The overall effect of this would be to improve diagnostic accuracy whilst at the same time increase the cost of HIV tests because of the high number of discrepant results which would need to be resolved by a third test.
ELISA or Western Blot kits that do more tests per box of reagent were found to be cheaper compared to those that do less. Confirmation of discordant results using a third ELISA kit3 would be 91.6% cheaper than using Western Blot.
The combination of Murex/Labsystems had the highest sensitivity and specificity com pared to the other combinations. However, the problem of the combination was that the Labsystems kit cannot detect antibodies to the HIV-1 Group O, neither does it detect IgM or IgA anti-HIV antibodies. The Labsystem kit detects the anti-HIV IgG antibodies only. Group O is a variant of the HIV-1 that was isolated in samples from Cameroon in West Africa in 1987 and recently in Europe and South America,1617 and since its discovery, specific epitopes from the envelope region of this virus have been used to detect antibodies to Group O in human serum. In Zimbabwe, HIV-1 subtype C predominates.16 However, with the World turning into a global village and people from various regions interacting constantly, it is advisable and wise to use kits that detect as many groups and subtypes of the HIV virus as is possible. Genelavia, which is currently in use at the NHLS, does not detect antibodies to Group O1 thus there is a need to replace it.
The earliest humoral immune response following HIV infection is the production of IgM antibodies with IgG antibodies being produced in a secondary immune response.|g Thus maximum sensitivity for detection of HIV infection is achieved by assays that detect both IgM and IgG antibodies. The detection of IgM antibody is also important in diagnosing newborn infections since, IgM does not cross the placenta as compared with IgG that crosses the placenta. A kit like Murex that detects IgA antibodies may also be of value in detecting HIV infection in infants under the age of two. 20 The exclusion of Labsy terns based on its inability to detect IgM antibodies and antibodies to HIV-1 group 0 antigens leaves out only three possible combinations, Murex/Innotest, Murex/Ice and Ice/Innotest.
Murex had the best sensitivity whilst Innotest had the best specificity. The combination of Murex/Innotest had the overall best results of 100% sensitivity and 98.9% specificity, making this combination a possible replacement for the Genelavia/Vironostika combination. Of the four kits evaluated, the Murex HIV-1.2.0 /Innotest HIV Ab 1.0.2 combination was the best requiring a relatively short time to run the assays, fewer controls included in the assays increase the number of patients' test specimens per run, with relatively fewer discordant samples to be resolved. Most importantly the combination maximizes HIV infection diagnosis as it detects antibodies to HIV-1 groups O and M as well as HIV-2.
In accordance with the WHO strategy III recommendation, there is a need to replace the expensive and unreliable WB with a combination of three ELISAs, with different antigen preparations and/or different test principles.4 6 7 As we have shown, replacement of Western Blot with a third ELISA allows for a considerable cost saving of about 91.6%. To evaluate a third ELISA as an alternative to Western blot, we recommend the use of the robust and more sensitive DNA PCR assay as the gold standard for assessing the HIV status of the samples to be used in the evaluation exercise. 2122 Recently, fourth generation ELISA kits, that combine two different test principles in one assay by permitting the simultaneous detection of the HIV p24 antigen along with anti HIV-1 (including subtype O) and HIV-2 IgG and IgM antibodies in a two phase reaction have been developed and arc already available in Europe. 23 These kits have been shown to permit an earlier diagnosis of HIV infection relative to the third generation kits included in this study, by detecting p24 antigen that may be present in samples from individuals with recent HIV infection prior to seroconversion. In these cases, the diagnostic window period was reduced by an average of nine days with fourth generation kits and was reduced by a further week by amplification of HIV-1 RNA from plasma or serum using PCR.2' The fourth ELISA generation kit would be particularly useful at the Blood Transfusion Services for identifying new infections before the seroconversion period. In addition, early diagnosis of HIV infection may be used for better patient management in terms of administration of prophylactic drugs to prevent infections with opportunistic microorganisms as well as prevention of the spread of infection by responsible individuals with knowledge of their HIV status. Most importantly, this kit, because of its superiority when compared to the third generation ELISA kits currently in use in Zimbabwe, may be used as the third confirmatory test in place of the expensive and unreliable WB.
